Scott Gottlieb resigns as head of FDABMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l1086 (Published 07 March 2019) Cite this as: BMJ 2019;364:l1086
- Janice Hopkins Tanne
- New York
The commissioner of the US Food and Drug Administration, Scott Gottlieb, has unexpectedly resigned after serving less than two years in the post.
Gottlieb announced his intention to stand down in a letter to Alex Azar II, secretary of the Department of Health and Human Services, the FDA’s parent agency, on 5 March.
Gottlieb said that he would leave within a month, as he was tired of the long commute to see his wife and three young children, who live in Connecticut. His resignation was a surprise, as in January he had denied rumours that he was quitting.
No successor has been named. A new commissioner must be approved by the US Senate.
In his resignation letter Gottlieb praised his FDA colleagues and their achievements, including “major new policies to reduce the …